Core Viewpoint - The A-share market is experiencing a downturn amid global market declines, with the ChiNext index falling over 1% and more than 4,000 stocks declining [1][2][4] Market Performance - A-shares showed resilience compared to significant declines in US and Japanese markets, with the Nasdaq dropping nearly 3% and Nikkei 225 over 4% [5] - The total trading volume in the two markets exceeded 1.2 trillion, with defensive sectors like precious metals, electricity, and banking rising against the trend, while sectors like photovoltaic and brokerage faced significant declines [4] Impact of Trump's Tariff Plan - Trump's upcoming announcement of a large-scale tariff plan, referred to as "liberation day," is expected to create volatility in global markets, affecting A-shares [8] - Analysts predict that the short-term pressure on A-shares will be significant, but the medium to long-term outlook remains resilient due to improved fundamentals and policy support [8][9] Sector Analysis - Industries with high export exposure, such as textiles, home appliances, and automotive parts, are likely to face significant impacts from the tariff plan [9] - Conversely, sectors like agriculture (due to high import dependence) and military (due to geopolitical uncertainties) may benefit from the situation [9] Investment Strategies - Investors are advised to adopt a cautious approach in the short term, considering increasing holdings in gold and high-dividend sectors while avoiding high-leverage technology stocks [9] - In the medium term, opportunities may arise in AI applications, consumer recovery, and domestic alternatives such as domestic chips and military sectors [9] Upcoming Earnings Reports - The upcoming earnings disclosure period in April is expected to see rapid style rotation in the market, with a focus on performance, dividends, and value [10][13] - The correlation between stock prices and earnings is anticipated to be strongest during this period, making it crucial for investors to pay attention to fundamentals [10][13] Sector Outlook - Three main directions are highlighted for investment based on earnings forecasts: 1. **Cyclical sectors** such as non-ferrous metals and engineering machinery are expected to show strong performance [15] 2. **Technology growth sectors** like SOC, semiconductor equipment, and memory interface chips are projected to have high earnings certainty [16][19] 3. **Dividend sectors** are expected to maintain stable growth, making them suitable for long-term investment [20]

Core Viewpoint - The active equity funds have regained market attention as the market conditions improve, with a notable focus on technology innovation-related themes [1][2][6] Group 1: Fund Issuance and Themes - As of March 20, a total of 17 new active equity funds have been launched, primarily focusing on technology innovation themes [1][2] - Among the 10 funds currently in the initial issuance phase, many are centered on technology sectors, including funds like Taiping Technology Pioneer Mixed and Deutsche Bank Emerging Industry Mixed [2] - Some funds are targeting specific themes, such as central enterprises and dividends, with examples like Rongtong Central Enterprise Selected Mixed focusing on high-dividend, stable cash flow companies [2][3] Group 2: Fund Issuance Strategies - Many funds are adopting a "initiated" issuance strategy due to concerns over unsuccessful fundraising, with 5 out of the 10 currently issuing funds being initiated funds [3][4] - Initiated funds require a minimum of 10 million yuan to establish and have shorter issuance periods, allowing for gradual scale growth post-establishment [4] Group 3: Fund Performance and Market Sentiment - Despite the increase in active equity fund issuance, there remains a cautious sentiment among fund companies due to recent failures in fundraising, with 3 funds reported to have failed to meet registration conditions this year [4][5] - The performance of active equity funds has shown promise, with the highest return exceeding 80% year-to-date, indicating potential for sustained performance as market conditions evolve [7]

Group 1: Market Overview - The A-share market experienced fluctuations with the North Securities 50 index down by 3.07% and the Sci-Tech 50 index down by 2.11%, while over 3,800 stocks declined, leading to a slight decrease in trading volume to 1.65 trillion yuan [1] - The coal, medical beauty, and electricity sectors showed relative strength, while humanoid robots, broadcasting, storage chips, and wireless earphones faced significant declines [1] - ST stocks continued to perform strongly, with *ST Xintong achieving a new high since January 2018, recording 31涨停 in 35 trading days [1] Group 2: Sector Performance - The coal industry saw a net inflow of over 3.3 billion yuan from major funds, while the banking and public utilities sectors each received over 2 billion yuan [1] - The power sector maintained strong performance, with the index rising for three consecutive days and trading volume exceeding 28.2 billion yuan, marking a new high for the year [2] - The artificial intelligence data center is expected to drive significant growth in electricity demand, with projections indicating that by 2026, global data center electricity consumption will reach between 620 billion and 1.05 trillion kilowatt-hours [2] Group 3: Company-Specific News - Qi Ming Medical, which had been suspended for over 15 months, saw its stock plummet by 66.37% upon resuming trading due to unauthorized fund transfers by former executives [3] - Qi Ming Medical acknowledged the challenges posed by the suspension and has undertaken a systematic restructuring of its organizational framework to enhance governance and internal controls [3] - The company has established a management committee to improve internal supervision and ensure timely market disclosures regarding significant matters [3]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].